and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual The consensus price target hints at a 212.5% upside potential for iTeos Therapeutics (ITOS).

and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos ...

Qingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China School of Medicine and ...